Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

By sjmartinez • September 10, 2024

Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. PMID: 39252866; PMCID: PMC11381616.

Tags: Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, long COVID, Monoclonal antibodies, outpatient treatment, PASC, Post COVID conditions, Post-acute sequelae of SARS-CoV-2 infection, Publications

FXYD2 marks and regulates maturity of (beta) cells via ion channel-mediated signal transduction

Tacto C, Tahbaz M, Salib A, Wang S, Cayabyab F, Choi J, Kim K, Hamba Y, Perez H, Gershon PD, Damoiseaux R, Oh TG, Yoshihara[...]

Comparative assessment of CAC and SIS plaque burden categories via AI-guided quantitative CT analysis

Iskander B, Ichikawa K, Punnanithinont N, Kambalapalli S, Kinninger A, Krishnan S, Lakshmanan S, Roy S, Budoff MJ. Comparative assessment of CAC and SIS plaque[...]

Reply: Keto CTA Study

Soto-Mota A, Norwitz NG, Manubolu VS, Kinninger A, Wood TR, Earls J, Feldman D, Budoff M. Reply: Keto CTA Study. JACC Adv. 2025 May 7;4(7):101862.[...]